On Thursday, Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT), added 6.49% and closed at $8.86 in the last trading session. The last trading range of the stock ranges between $8.56 and $9.04. Corcept Therapeutics Incorporated ( NASDAQ : CORT )
Third quarter revenue of $21.7 million, a 64 percent increase from the third quarter of 2015
Third quarter GAAP net income of $0.02 per share, contrast to a GAAP net loss of $0.01 per share in the third quarter of 2015
Apart From non-cash expenses, third quarter non-GAAP net income of $0.04 per share, contrast to non-GAAP net income of $0.02 per share in the third quarter of 2015
Company increases 2016 revenue guidance to $79-82 million
Cash balance at September 30, 2016 increases to $47.9 million
Tronox Ltd (NYSE:TROX), dropped -0.52% and closed at $9.50 in the last trading session. The last trading range of the stock ranges between $9.48 and $9.99. The company’s Market capitalization is $622.18 million with the total Outstanding Shares of 65.15 million. Tronox Limited (TROX) declared recently, effective January 1, 2017 or as contract terms permit, its Tronox Alkali business will increase list and off-list prices for all U.S. Pharmacopeia (USP) and Industrial grade sodium bicarbonate products by $15 per ton, Free On Board, Green River, Wyo., USA.
Intrexon Corp (NYSE:XON), jumped 4.62% and closed at $29.42 in the last trading session. The last trading range of the stock ranges between $27.14 and $29.75. During the 52-week trading session the minimum price at which share price traded, registered at $18.52 and reached to max level of $43.76. Fibrocell Science, Inc. (FCSC) recently declared the appointment of Alfred T. Lane, MD, as Chief Medical Advisor of Fibrocell. A board certified dermatologist and pediatrician, Dr. Lane is a Professor of Dermatology and Pediatrics (Emeritus) at Stanford University School of Medicine and the former Chair of the Department of Dermatology where he led a research team focused on developing gene therapy for Epidermolysis Bullosa (EB) and other genetic skin diseases.
“We are delighted to have Dr. Lane join Fibrocell as our Chief Medical Advisor,” said David Pernock, Chairman and Chief Executive Officer of Fibrocell. “Dr. Lane’s dedication to pediatric dermatology is respected worldwide and his commitment to assisting patients and families influenced by EB and other devastating skin diseases is remarkable. We believe his insight will be invaluable to assist us advance clinical development of FCX-007, our gene-therapy candidate for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB).”